Status:
COMPLETED
Use Of Fragmin In Hemodialysis
Lead Sponsor:
Pfizer
Conditions:
Chronic Renal Failure
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.
Eligibility Criteria
Inclusion
- chronic renal failure on hemodialysis
Exclusion
- significant comorbidities that would prevent a patient from completing the trial
Key Trial Info
Start Date :
October 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT01879618
Start Date
October 1 2013
End Date
March 1 2016
Last Update
March 10 2017
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Alexandra Hospital
Edmonton, Alberta, Canada, T5G 0B8
2
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
3
Grey Nuns Community Hospital
Edmonton, Alberta, Canada, T6L 5X8
4
Horizon Health Network/Saint John Regional Hospital
Saint John, New Brunswick, Canada, E2L 4L2